Scienture Holdings, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Scienture Holdings, Inc. now
Current reporting with the operating signal separated from the noise.
Scienture Holdings, Inc.: Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
The development tests whether Scienture Holdings, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc.: SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
The story matters when it changes Scienture Holdings, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
The story matters when it changes Scienture Holdings, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
Investors are testing whether Scienture Holdings, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
The development tests whether Scienture Holdings, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
The development tests whether Scienture Holdings, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc. Appoints Michele Rath as Senior Vice President and Chief Commercial Officer
The story matters when it changes Scienture Holdings, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Scienture Holdings, Inc. Secures Exclusive U.S. Rights for REZENOPY® Naloxone Nasal Spray to Combat Opioid Overdose
The story matters when it changes Scienture Holdings, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest SCNX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Scienture Holdings, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →